In this pharmacology effectiveness study supporting the combination of HER-Vaxx with a PD1 checkpoint, the mouse PD1- derived vaccine (JT-mPD1, 50 μg/dose) in combination with HER-Vaxx vaccine (25 μg/dose), enhanced the anti-tumor effect in vivo in the mouse syngeneic tumor model (D2F2/E2 cells (BALB/c mouse mammary carcinoma cells expressing HER-2/neu) as previously reported (25). Here, ERBB2 is linked to breast carcinoma.